文献速递消化道肿瘤与早癌

三级淋巴结构相关B细胞增强胃癌中CXCL13+CD103+CD8+组织驻留记忆T细胞对程序性细胞死亡蛋白1阻断的应答

Tertiary Lymphoid Structure-Associated B Cells Enhance CXCL13+CD103+CD8+ Tissue-Resident Memory T-Cell Response to Programmed Cell Death Protein 1 Blockade in Cancer Immunotherapy.
PubMed 文献 · Gastroenterology · 2023-10-29

本研究在胃癌患者肿瘤切片中检测三级淋巴结构(TLS)及CXCL13+CD103+CD8+组织驻留记忆T(Trm)细胞,通过体外和体内实验探讨B细胞与该Trm细胞的通讯机制,并评估抗PD-1治疗中该Trm细胞抑制肿瘤生长的作用。结果显示TLS和CXCL13+CD103+CD8+ Trm细胞的存在与胃癌患者抗PD-1治疗更优应答相关,活化B细胞通过淋巴毒素-α/TNFR2轴促进CD103+CD8+ Trm细胞糖酵解并增强CXCL13和颗粒酶B分泌。

要点

  • 胃癌肿瘤组织中TLS和CXCL13+CD103+CD8+ Trm细胞的存在与抗PD-1治疗更优应答相关。
  • 活化B细胞增强CD103+CD8+ Trm细胞分泌CXCL13和颗粒酶B。
  • B细胞通过淋巴毒素-α/TNFR2轴促进CD103+CD8+ Trm细胞糖酵解,mTOR信号通路起关键作用。

核心结论

  • 本研究揭示TLS相关B细胞与CXCL13+CD103+CD8+ Trm细胞之间的细胞通讯在抗肿瘤免疫中起关键作用,为利用CXCL13+CD103+CD8+ Trm细胞内的淋巴毒素-α/TNFR2轴推进胃癌免疫治疗策略提供见解。

研究设计与样本

  • 对胃癌患者肿瘤切片进行TLS及CXCL13+CD103+CD8+ Trm细胞的免疫组化和H&E染色。
  • 体外和体内实验确定B细胞与CXCL13+CD103+CD8+ Trm细胞间的通讯机制。
  • 通过抗PD-1治疗评估CXCL13+CD103+CD8+ Trm细胞抑制肿瘤生长的作用。

主要发现

  • 胃癌患者肿瘤组织中TLS和CXCL13+CD103+CD8+ Trm细胞的存在与抗PD-1治疗更优应答相关。
  • 活化B细胞增强CD103+CD8+ Trm细胞分泌CXCL13和颗粒酶B。
  • B细胞通过淋巴毒素-α/TNFR2轴促进CD103+CD8+ Trm细胞糖酵解,mTOR信号通路在此过程中起关键作用。
  • TLS和CXCL13+CD103+CD8+ Trm细胞的存在以TNFR2依赖方式与抗PD-1治疗强应答相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Although the presence of tertiary lymphoid structures (TLS) correlates with positive responses to immunotherapy in many solid malignancies, the mechanism by which TLS enhances antitumor immunity is not well understood. The present study aimed to investigate the underlying cross talk circuits between B cells and tissue-resident memory T (Trm) cells within the TLS and to understand their role in the context of immunotherapy. METHODS: Immunostaining and H&E staining of TLS and chemokine (C-X-C motif) ligand 13 (CXCL13)+ cluster of differentiation (CD)103+CD8+ Trm cells were performed on tumor sections from patients with gastric cancer (GC). The mechanism of communication between B cells and CXCL13+CD103+CD8+ Trm cells was determined in vitro and in vivo. The effect of CXCL13+CD103+CD8+ Trm cells in suppressing tumor growth was evaluated through anti-programmed cell death protein (PD)-1 therapy. RESULTS: The presence of TLS and CXCL13+CD103+CD8+ Trm cells in tumor tissues favored a superior response to anti-PD-1 therapy in patients with GC. Additionally, our research identified that activated B cells enhanced CXCL13 and granzyme B secretion by CD103+CD8+ Trm cells. Mechanistically, B cells facilitated the glycolysis of CD103+CD8+ Trm cells through the lymphotoxin-α/tumor necrosis factor receptor 2 (TNFR2) axis, and the mechanistic target of rapamycin signaling pathway played a critical role in CD103+CD8+ Trm cells glycolysis during this process. Moreover, the presence of TLS and CXCL13+CD103+CD8+ Trm cells correlated with potent responsiveness to anti-PD-1 therapy in a TNFR2-dependent manner. CONCLUSIONS: This study further reveals a crucial role for cellular communication between TLS-associated B cell and CXCL13+CD103+CD8+ Trm cells in antitumor immunity, providing valuable insights into the potential use of the lymphotoxin-α/TNFR2 axis within CXCL13+CD103+CD8+ Trm cells for advancing immunotherapy strategies in GC.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Hu C, You W, Kong D, et al. Tertiary Lymphoid Structure-Associated B Cells Enhance CXCL13+CD103+CD8+ Tissue-Resident Memory T-Cell Response to Programmed Cell Death Protein 1 Blockade in Cancer Immunotherapy. Gastroenterology. 2023. PMID: 38445519. doi:10.1053/j.gastro.2023.10.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。